Author(s):
Vijaykumar T. Pawar, Mrunalee D. Magadum
Email(s):
magadummrunalee@gmail.com
DOI:
10.52711/2231-5675.2023.00041 
Address:
Vijaykumar T. Pawar1, Mrunalee D. Magadum2*
1Assistant Professor, Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur - 416013 Maharashtra, India.
2Student, Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur - 416013 Maharashtra, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 4,
Year - 2023
ABSTRACT:
Objective: There are several methods for analyzing the same, however, they are time-consuming and costly. We created a new spectrophotometric method for determining Dolutegravir (DLT) in tablet dosage forms that is simple, accurate, and precise. We developed and validated a simple, accurate, and precise colorimetric method for the quantitative analysis of Dolutegravir in bulk and dosage form by ICH recommendations in this study. Methodology: There are several methods for analyzing the same, however, they are time-consuming and costly. We created a new spectrophotometric method for determining Dolutegravir (DLT) in tablet dosage forms that is simple, accurate, and precise. In methanol, the initial stock solution of Dolutegravir was prepared. The method is based on the formation of a blue color chromogen complex from Dolutegravir oxidation-reduction with Ferric chloride in the presence of potassium ferricyanide. Result: The color complex was measured at 710nm. Beers law was observedin the concentration range of 3.5-6.5µg/ml witha coefficient of correlation (R2) was 0.998. The system suitability criteria were found to be within the limits. The LOD and LOQ were found to be 0.91 and 2.47, indicating that the method is sensitive. Conclusion: The relative standard deviation (RSD) and percent recovery values were found to be satisfactory, indicating that the proposed method is suitable, accurate, and precise and that it can be used in routine analysis of Dolutegravir in tablet dosage forms, with relatively low-cost solvents.
Cite this article:
Vijaykumar T. Pawar, Mrunalee D. Magadum. Development of Visible Spectrophotometric Method and its Validation for Dolutegravir in Tablet Dosage Form. Asian Journal of Pharmaceutical Analysis. 2023; 13(4):249-4. doi: 10.52711/2231-5675.2023.00041
Cite(Electronic):
Vijaykumar T. Pawar, Mrunalee D. Magadum. Development of Visible Spectrophotometric Method and its Validation for Dolutegravir in Tablet Dosage Form. Asian Journal of Pharmaceutical Analysis. 2023; 13(4):249-4. doi: 10.52711/2231-5675.2023.00041 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2023-13-4-5
REFERENCE:
1. United States Food and Drug Administration, FDA. Approves new drug to treat HIV infection http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm [Access Online Aug. 12, 2013].
2. Min S, Song I, Borland J, Chen S, Lou Y, Fujjwara T, Piscitelli SC.Pharmacokinetics and safety of S/GSK1349572, a next-generation HIVintegrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010; 54(1):254–258. URL:https://doi.org/10.1128/AAC.00842-09.
3. Ribera E, Podzamczer D.Mechanisms of action, pharmacology and interactions of Dolutegravir. Enferm Infecc Microbiol Clin. 2015; 33(1):2–8.URL: https://doi.org/10.1016/s0213-005x(15)30002-1.
4. Mastannama SK, Ananta Sridhar T, Saidulu P. A novel UVspectrophotometric method development and validation of Dolutegravir in bulk and its laboratory synthetic mixture by using 8 M urea as a hydrotropic solubilizing agent. Int J Pharm Sci Drug Res. 2015; 7(4):370–375. URL:http://ijpsdr.com/index.php/ijpsdr/article/view/439.
5. Girija BB, Kiran AB, Ravindra TS, Kakadsachein J, Sanjay Sudhakar P. Development and validation of UV spectrophotometric method for estimation of Dolutegravir sodium in the tablet dosage form. Malaysian J Anal Sci. 2015; 19(6): 1156–1163.
6. Yashpalsinh NG, Rao S, Soni D. Development and validation of chiral RP-HPLC method for quantification of optical isomers in Dolutegravir sodium. Der Pharmacia Lettre. 2018; 10(9):90–100.
7. Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, Lou Y, Min S S, Goljer I, Culp A, Piscitelli S C, and Savina P M . Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor, Dolutegravir, in humans. Antimicrobial Agents and Chemotherapy. 2013; 57(8): 3536 – 3546.
8. Girija BB, Sanjay SP, Kiran AB, Ravindra TS, Thorat RC. Highperformance liquid chromatographic and high-performance thin-layer chromatographic method for the quantitative estimation of Dolutegravir sodium in bulk drug and pharmaceutical dosage form. Sci Pharm. 2016; 84(2): 305-320. URL: https://doi.org/10.3797/scipharm.1507-09.
9. Shalini SP, Lavakesh Kumar O. New analytical method development and validation for estimation of Dolutegravir sodium in synthetic mixture using RP-HPLC. Asian J Pharm Edu Res. 2018; 7(4):48–56.
10. Wang X, Penchala SD, Amara A, Else L, McClure M, Boffito M. A validated method for quantification of Dolutegravir using ultra-performance liquid chromatography coupled with UV detection. Ther Drug Monit. 2016; 38(3): 327–331. URL: https://doi.org/10.1097/FTD.0000000000000286.
11. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown K W, Ferris R, Foster S A, Hazen R J, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi, T, Kawasuji T, Johns B A, Underwood M R, Garvey E P, Sato A and Fujiwara T. In vitroantiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrobial Agents and Chemotherapy. 2011; 55: 813 – 821.
12. Min S, Sloan L, De Jesus E, Hawkins T, McCurdy L, Song I, Stroder R, Chen S, Underwood M, Fujiwara T, Piscitelli S and Lalezari J. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of Dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011; 25(14): 1737 – 1745.
13. Reese MJ, Savina P M, Generaux G T and Tracey H, Humphreys J E, Kanaoka E, Webster L O, Harmon K A, Clarke J D and Polli J W. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of Dolutegravir, a HIV integrase inhibitor. Drug Metabolism and Disposition. 2013; 41: 353 – 361.
14. Chandrashekar Reddy K, Pavan Kumar KSR, Jagadeesh KV, Srinivas N, SharmaHK, Mukkanti K. Stability-indicating HPLC method for thequantification (4S, 12R)-enantiomer and (4R, 12S)-diastereomer inDolutegravir sodium. Int J Pharm Pharm Res. 2017; 9(2):52–63.
15. Satyadev TNVSS, Bhargavi C, Syam Sundar B. Development andvalidation of HPLC method for the determination of Dolutegravir in humanplasma. Der Pharmacia Sinica. 2015; 6(4): 65–72.
16. Chantelle-Bennetto-Hood GT, Savina P, Edward P, Acosta. A sensitiveHPLC-MS/MS method for the determination of Dolutegravir in humanplasma. J Chromatography B Analyt Technol Biomed Life Sci. 2014; 15: 225–232. URL: https://doi.org/10.1016/j.jchromb.2013.11.054.
17. ICH, Q2 (R1). Validation of Analytical Procedures: Text andMethodology: International Conference on Harmonization. 2005.
18. Rathod S, Mali S, Shinde N, Aloorkar N. Cosmeceuticals and Beauty Care Products: Current trends with future prospects. Research Journal of Topical and Cosmetic Sciences. 2020; 11(1): 45-51.
19. Rathod S, Shinde K, Shinde N, Aloorkar N. Cosmeceuticals and nanotechnology in beauty care products. Research Journal of Topical and Cosmetic Sciences. 2021; 12(2): 93-101.
20. Kale N, Rathod S, More S, Shinde N. Phyto-Pharmacological Profile of Wrightia tinctoria. Asian Journal of Research in Pharmaceutical Sciences. 2021 Nov 26; 11(4): 301-8.
21. Bendre S, Shinde K, Kale N, Gilda S. Artificial Intelligence in Food Industry: A Current Panorama. Asian Journal of Pharmacy and Technology. 2022 Aug 10; 12(3):242-50.
22. Mali S, Rathod S, Kale N, Shinde N. Overview of Nutraceuticals. Asian Journal of Pharmaceutical Research. 2022; 12(1):61-70.
23. Shinde K, Bendre S, Kale N, Gilda S. The mRNA Vaccine Heralds a New Era in Vaccinology. Asian Journal of Pharmacy and Technology. 2022; 12(3): 257-65.
24. Mali S, Bendre S, Patil S. Overview of Pharmacognostical and Pharmacological properties of Moringa oleifera. Asian Journal of Pharmacy and Technology. 2022; 12(1):77-83.
25. Shinde N, Bangar B, Deshmukh S, Kumbhar P. Nutraceuticals: A Review on current status. Research Journal of Pharmacy and Technology. 2014; 7(1):110-3.
26. Kurund P, Gandla S. Pharmacognostical, Phytochemical and Anti-Parkinson’s profile of Mucuna pruriens. Research Journal of Pharmacology and Pharmacodynamics. 2021; 13(4):125-30.